Mutual of America Capital Management LLC Sells 586 Shares of STERIS plc (NYSE:STE)

Mutual of America Capital Management LLC reduced its stake in STERIS plc (NYSE:STE) by 4.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 13,251 shares of the medical equipment provider’s stock after selling 586 shares during the quarter. Mutual of America Capital Management LLC’s holdings in STERIS were worth $2,913,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in STE. Yousif Capital Management LLC boosted its position in shares of STERIS by 0.7% in the 1st quarter. Yousif Capital Management LLC now owns 15,327 shares of the medical equipment provider’s stock worth $3,706,000 after purchasing an additional 106 shares in the last quarter. Vontobel Holding Ltd. boosted its position in shares of STERIS by 25.6% in the 1st quarter. Vontobel Holding Ltd. now owns 1,919 shares of the medical equipment provider’s stock worth $471,000 after purchasing an additional 391 shares in the last quarter. Blair William & Co. IL boosted its position in shares of STERIS by 8.1% in the 1st quarter. Blair William & Co. IL now owns 13,523 shares of the medical equipment provider’s stock worth $3,269,000 after purchasing an additional 1,010 shares in the last quarter. Cetera Investment Advisers boosted its position in shares of STERIS by 24.4% in the 1st quarter. Cetera Investment Advisers now owns 2,345 shares of the medical equipment provider’s stock worth $567,000 after purchasing an additional 460 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in STERIS by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 11,525,769 shares of the medical equipment provider’s stock valued at $2,786,586,000 after acquiring an additional 143,253 shares in the last quarter. 94.69% of the stock is owned by institutional investors.

STERIS Price Performance

Shares of STE opened at $200.71 on Friday. The firm has a market cap of $19.83 billion, a PE ratio of 35.15 and a beta of 0.79. The company has a current ratio of 2.43, a quick ratio of 1.49 and a debt-to-equity ratio of 0.50. The firm has a fifty day simple moving average of $224.20 and a two-hundred day simple moving average of $217.59. STERIS plc has a 1-year low of $180.54 and a 1-year high of $254.00.

STERIS (NYSE:STE) last announced its earnings results on Wednesday, February 7th. The medical equipment provider reported $2.22 earnings per share for the quarter, beating analysts’ consensus estimates of $2.17 by $0.05. The business had revenue of $1.40 billion during the quarter, compared to analyst estimates of $1.35 billion. STERIS had a net margin of 10.48% and a return on equity of 13.67%. The company’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same period in the previous year, the business earned $2.02 EPS. On average, equities analysts anticipate that STERIS plc will post 8.67 EPS for the current year.

STERIS Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 22nd. Shareholders of record on Friday, February 23rd were paid a dividend of $0.52 per share. The ex-dividend date of this dividend was Thursday, February 22nd. This represents a $2.08 dividend on an annualized basis and a yield of 1.04%. STERIS’s dividend payout ratio is presently 36.43%.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. TheStreet raised STERIS from a “c+” rating to a “b” rating in a research report on Wednesday, February 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research report on Friday, April 12th. Stephens reaffirmed an “overweight” rating and issued a $250.00 price objective on shares of STERIS in a research report on Friday, February 9th. KeyCorp assumed coverage on STERIS in a research report on Tuesday, February 6th. They issued an “overweight” rating and a $253.00 price objective on the stock. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a research report on Thursday, February 8th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, STERIS presently has a consensus rating of “Moderate Buy” and a consensus target price of $239.60.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.